BR0011159A - Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences - Google Patents

Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences

Info

Publication number
BR0011159A
BR0011159A BR0011159-7A BR0011159A BR0011159A BR 0011159 A BR0011159 A BR 0011159A BR 0011159 A BR0011159 A BR 0011159A BR 0011159 A BR0011159 A BR 0011159A
Authority
BR
Brazil
Prior art keywords
virus
recombinant
negative
attenuated
mutant
Prior art date
Application number
BR0011159-7A
Other languages
Portuguese (pt)
Inventor
Peter L Collins
Brian R Murphy
Anna P Durbin
Mario H Skiadopoulos
Original Assignee
Government Of The Us Dept Of H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Dept Of H filed Critical Government Of The Us Dept Of H
Publication of BR0011159A publication Critical patent/BR0011159A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODO PARA PRODUZIR VACINAS DE VìRUS RNA DE FITA NEGATIVA ATENUADO A PARTIR DE SEQuêNCIAS DE NUCLEOTìDEOS CLONADOS". Vírus RNA de fita negativa recombinantes, atenuados, adequados para uso como vacinas são produzidos a partir de uma ou mais moléculas de polinucleotídeos isoladas codificando o vírus. Um genoma recombinante ou antigenoma do vírus em questão é modificado para codificar uma mutação dentro de uma proteína recombinante do vírus em uma ou mais posições de aminoácido correspondentes a um local de uma mutação atenuante em um vírus RNA de fita negativa mutante, heterólogo. Uma mutação atenuante similar como identificada no vírus RNA de fita negativa mutante, heterólogo, é portanto incorporada em um local correspondente dentro do vírus recombinante para conferir um fenótipo atenuado no vírus recombinante. A mutação atenuante incorporada no vírus recombinante pode ser idêntica ou conservativa em relação à mutação atenuante identificada no vírus mutante, heterólogo. Pela transferência de mutações para dentro de vírus RNA de fita negativa recombinantes desta maneira, vírus candidatos a vacina são engenheirados para gerar uma resposta imunológica contra um vírus em questão em um hóspede suscetível a infecção desta forma."METHOD TO PRODUCE ATTENUATED NEGATIVE TAPE RNA VIRUSES ATTENUATED FROM CLONED NUCLEOTIDE SEQUENCES". Recombinant, attenuated, negative-stranded RNA viruses suitable for use as vaccines are produced from one or more isolated polynucleotide molecules encoding the virus. A recombinant genome or antigenome of the virus in question is modified to encode a mutation within a recombinant virus protein at one or more amino acid positions corresponding to a site of an attenuating mutation in a mutant, heterologous negative strand RNA virus. A similar attenuating mutation as identified in the heterologous mutant negative strand RNA virus is therefore incorporated at a corresponding location within the recombinant virus to confer an attenuated phenotype in the recombinant virus. The attenuating mutation incorporated in the recombinant virus can be identical or conservative in relation to the attenuating mutation identified in the mutant, heterologous virus. By transferring mutations into recombinant negative stranded RNA viruses in this manner, vaccine candidate viruses are engineered to generate an immune response against a virus in question in a host susceptible to infection in this way.

BR0011159-7A 1999-04-13 2000-04-12 Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences BR0011159A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12900699P 1999-04-13 1999-04-13
PCT/US2000/009695 WO2000061737A2 (en) 1999-04-13 2000-04-12 Production of attenuated negative stranded rna virus vaccines

Publications (1)

Publication Number Publication Date
BR0011159A true BR0011159A (en) 2002-07-23

Family

ID=22438049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011159-7A BR0011159A (en) 1999-04-13 2000-04-12 Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences

Country Status (10)

Country Link
EP (1) EP1171623A2 (en)
JP (1) JP4646410B2 (en)
KR (1) KR100760328B1 (en)
CN (1) CN1347458A (en)
AU (2) AU781238B2 (en)
BR (1) BR0011159A (en)
CA (1) CA2369817A1 (en)
IL (1) IL145797A0 (en)
MX (1) MXPA01010392A (en)
WO (1) WO2000061737A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
BR9710363A (en) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "Isolated infectious recombinant respiratory syncytial virus, particulate, processes to stimulate an individual's immune system to induce protection against respiratory syncytial virus and to produce a particle of recombinant respiratory syncytial virus, vaccine to induce protection against recombinant respiratory syncytial virus. composition and collection of recombinant respiratory syncytial virus "
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
JP2003530073A (en) 1999-07-09 2003-10-14 アメリカ合衆国 Production of an attenuated human-bovine chimeric respiratory syncytial virus vaccine
ATE307606T1 (en) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee ATTENUATED MUTANT STRAIN OF NEWCASTLE DISEASE VIRUS FOR IN OVO VACCINATION AND USE THEREOF
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
BRPI0411247A (en) 2003-06-09 2006-07-25 Wyeth Corp improved process for recovering non-segmented negative filament rna viruses from cdna
KR20090114431A (en) * 2007-02-07 2009-11-03 디나벡크 가부시키가이샤 Attenuated minus-stranded RNA virus
JP2013531496A (en) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ Recombinant RNA virus and use thereof
CN103525777B (en) * 2013-07-01 2016-05-18 中国农业科学院兰州兽医研究所 Attenuated vaccine strain of VII type NDV L gene mutation and preparation method thereof
AU2018298499B2 (en) * 2017-07-03 2024-07-18 Bharat Biotech International Limited A synthetic polypeptide epitope based vaccine composition
KR20200096904A (en) * 2017-09-15 2020-08-14 오하이오 스테이트 이노베이션 파운데이션 Vaccines for the prevention of respiratory syncytial virus (RSV) infection and methods of making and using vaccines
CN111019910B (en) * 2019-11-04 2022-03-15 上海青赛生物科技有限公司 F genotype mumps virus attenuated strain, construction method and application thereof
CN111849927B (en) * 2020-06-28 2022-07-08 浙江大学 Method for efficiently producing recombinant nonsegmented negative-sense RNA virus and recombinant virus
CN116676275B (en) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A-genotype chimeric mumps virus strain and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
BR9710363A (en) * 1996-07-15 2000-01-11 Us Gov Health & Human Serv "Isolated infectious recombinant respiratory syncytial virus, particulate, processes to stimulate an individual's immune system to induce protection against respiratory syncytial virus and to produce a particle of recombinant respiratory syncytial virus, vaccine to induce protection against recombinant respiratory syncytial virus. composition and collection of recombinant respiratory syncytial virus "

Also Published As

Publication number Publication date
JP4646410B2 (en) 2011-03-09
AU4231500A (en) 2000-11-14
MXPA01010392A (en) 2003-09-15
CN1347458A (en) 2002-05-01
AU2005203596C1 (en) 2009-12-10
AU2005203596B8 (en) 2009-12-10
AU2005203596B2 (en) 2008-09-11
AU2005203596A1 (en) 2005-09-08
EP1171623A2 (en) 2002-01-16
KR20020008831A (en) 2002-01-31
IL145797A0 (en) 2002-07-25
JP2002541798A (en) 2002-12-10
KR100760328B1 (en) 2007-10-04
AU781238B2 (en) 2005-05-12
CA2369817A1 (en) 2000-10-19
WO2000061737A2 (en) 2000-10-19
WO2000061737A3 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
BR0011159A (en) Method for producing attenuated negative strand virus RNA vaccines from cloned nucleotide sequences
KR100927517B1 (en) Live vaccine
NZ586238A (en) Methods and compositions for immunizing pigs against porcine circovirus
AU2019321186B2 (en) Immunogenic compositions and uses thereof
RU2011104999A (en) HEMAGGLUTININ AND INFLUENZA VIRUS NEURAMIDASE OPTIONS
CY1106883T1 (en) Recombinant EVOLOGY VIRUS CONTAINING TWO MOVEMENTS AGAINST EVOLOGY ANGEL.
JP2002542827A5 (en)
JP2012531205A5 (en)
JP2013523718A5 (en)
WO2001060849A2 (en) Cold-adapted equine influenza viruses
WO2006038742A1 (en) Recombinant virus and use thereof
KR20140031912A (en) Canine influenza recombinant virus, preparation method therefor and application thereof
WO2005054451A1 (en) Highly safe smallpox vaccine virus and vaccinia virus vector
RU2013102413A (en) PARAPOXVIRAL VECTORS
JP2012517239A5 (en)
RU2011137404A (en) HEMAGGLUTININ AND INFLUENZA INFLUENZA OPTIONS
Becker et al. Gene cloning and complete nucleotide sequence of Philippine Schistosoma japonicum paramyosin
JP6988015B1 (en) Thermostable Newcastle disease virus mutant strain, its production method, and use
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
JP2024500225A (en) Genomic deletion in African swine fever vaccine that allows efficient growth in stable cell lines
Zhang et al. A single amino acid change restores DNA cytosine methyltransferase activity in a cloned chlorella virus pseudogene
CN112111467A (en) Gene VII-type newcastle disease marker vaccine strain and preparation method and application thereof
Graves et al. Characterization of the gene encoding the most abundant in vitro translation product from virus-infected Chlorella-like algae
Joklik et al. Virulence genes of poxviruses and reoviruses
Widdison et al. Characterisation of bovine inducible nitric oxide synthase

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.